208 related articles for article (PubMed ID: 7866991)
1. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.
Morikage T; Ohmori T; Nishio K; Fujiwara Y; Takeda Y; Saijo N
Cancer Res; 1993 Jul; 53(14):3302-7. PubMed ID: 8391922
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
7. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.
Bungo M; Fujiwara Y; Kasahara K; Nakagawa K; Ohe Y; Sasaki Y; Irino S; Saijo N
Cancer Res; 1990 May; 50(9):2549-53. PubMed ID: 2158392
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
9. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
11. Significance of Na+, K(+)-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines.
Bando T; Fujimura M; Kasahara K; Matsuda T
Anticancer Res; 1998; 18(2A):1085-9. PubMed ID: 9615770
[TBL] [Abstract][Full Text] [Related]
12. Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines.
Bando T; Kasahara K; Shibata K; Nakatsumi Y; Fujimura M; Matsuda T
Anticancer Res; 1994; 14(6B):2727-30. PubMed ID: 7872708
[TBL] [Abstract][Full Text] [Related]
13. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
[TBL] [Abstract][Full Text] [Related]
16. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
